Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Anti-5c8 - IDEC; Anti-CD154 - IDEC; Anti-CD40L - IDEC; Anti-gp39 - IDEC; Anti-gp39 monoclonal antibody - IDEC; Anti-T-BAM - IDEC; Anti-TRAP - IDEC; E 6040; IDEC 131

Latest Information Update: 05 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IDEC Pharmaceuticals
  • Developer Eisai Co Ltd; IDEC Pharmaceuticals; Seikagaku Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Crohn's disease; Idiopathic thrombocytopenic purpura; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 04 Aug 2004 Phase-I clinical trials in Autoimmune disorders in Japan (unspecified route)
  • 30 Apr 2003 IDEC Pharmaceutical is working with the FDA to remove the clinical hold status on IDEC 131
  • 09 Apr 2003 Data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) was added to the adverse events section and the Skin therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top